title: Prognostic implication of p27 expression in primary central nervous system lymphoma.
abstract: To clarify the role of p27/Kip1 (p27) in primary central nervous system lymphomas (PCNSLs), we examined p27 expression by immunohistochemical methods in a series of 22 patients with PCNSL. We attempted to correlate the expression of p27 with proliferation potential and prognosis. Although the MIB-1 labeling index (LI) was lower in tumors with low p27 expression (26.7% +/- 17.2% vs 38.1% +/- 16.3%), it was not significantly different from that of tumors with high p27 expression (P = 0.1253). Survival analysis revealed that high p27 expression was significantly associated with poorer overall prognosis (P = 0.0011); however, the MIB-1 LI were not associated with prognosis. Our results suggest p27 as a predictor of prognosis in patients with PCNSL.
authors: Department of Neurosurgical Surgery, Kagawa University, Kagawa, Japan. k.kunisho@kawasaki-hp.jp
authors: Katsuzo
authors: K
authors: Kunishio
authors: Seigo
authors: S
authors: Nagao
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002467:Cell Nucleus / Q000473:pathology; D016543:Central Nervous System Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D004396:Coloring Agents; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000096:biosynthesis* / Q000235:genetics*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004268:DNA-Binding Proteins / Q000378:metabolism; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008223:Lymphoma / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016612:Paraffin Embedding; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D016707:Tissue Fixation; D014157:Transcription Factors / Q000378:metabolism; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014408:Biomarkers, Tumor; D004396:Coloring Agents; D004268:DNA-Binding Proteins; D014157:Transcription Factors; D050760:Cyclin-Dependent Kinase Inhibitor p27; C077171:HIVEP2 protein, human; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone